Clinical Trial Update: A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of talazoparib in men with DNA repair defects and metastatic castration-resistant prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-09-08